A healthy world encompasses more than just the idea of well-being. It involves ensuring access to high-quality medicines at reasonable prices for patients, as everyone deserves fair and affordable healthcare. While significant strides have been made in the production of new medicines for various health conditions, many patients still require assistance. For instance, the International Diabetes Federation anticipates that the number of people with diabetes in South and Central America will rise by 48% to reach 49 million by 2045, with one out of every three individuals living with undiagnosed diabetes.
This is where companies like Luminova Pharma Group (LPG) come in as leaders in pharmaceutical distribution and commercialization, with a mission to deliver more healthcare solutions to Latin America and expand their contribution to health and well-being.
As Luminova Pharma Group celebrates its sixtieth anniversary this year, it's worth reflecting on the company's history, which began with its inception as Unipharm in 1963. The organization has undergone a significant transformation since then, but its legacy lives on.
Luminova Pharma Group is a leading world-class pharmaceutical quality organization in Latin America, offering innovative healthcare solutions to ensure access, quality of life, and wellness for patients. Over the past sixty years, The company has had a presence in Central America, Colombia, Ecuador and Dominican Republic. The company has successfully expanded its reach and brought healthcare solutions to new markets, including Bolivia, Perú, and the West Indies where it now serves a population of 20 million as of 2022. During this time, LPG has launched over fifty molecules/medicines in cardiovascular, diabetes, pain relief, antibiotics, and gastroenterology therapies across different countries, benefiting local communities in various ways.
Luminova Pharma Group’s first party portfolio includes: Unipharm, acute; Uninova, chronic; Uninutra, multivitamins and supplements; and Novum, non-branded portfolio. LPG's strategic alliances with partners such as Sanulac (France), Novartis (Switzerland), and Apotex (Canada) have been instrumental in distributing and representing their health solutions in Central America and the Caribbean, particularly in infant formulas, respiratory, and pain relief therapies. Through its subsidiary company, Medwell, the company represents third-party brands to ensure a wider range of healthcare solutions in Latin America.
The Foundation Aldo Castañeda is a non-profit Guatemalan organization committed to improving the life expectancy of thousands of children born with heart malformations, by providing diagnosis, care, and corrective surgery. The foundation's efforts have given life expectancy to children in Central America and the Dominican Republic.
Mike Erichsen, President of Luminova Pharma Group, and Dr. Gonzalo Calvimontes , Vice President of Foundation Aldo Castañeda, delve into the foundation's main vision of raising funds and providing care for patients with congenital heart disease, using a specialized medical team and advanced technology. In Guatemala, due to insufficient funding, only 24% of children manage to receive a diagnosis and treatment, leaving the majority of children born with heart malformations unable to access care, which often results in their untimely death within the first year of life.
As of 2018, the foundation had trained around 100 paediatric cardiac surgeons, as well as medical personnel, nurses, and technicians. The foundation has also been continuously acquiring high-tech medical equipment and materials to develop a Unit of Cardiology and Congenital Cardiac Surgery that is unique in Central America.
In the years to come, Luminova Pharma Group plans to extend its services to over 30 million patients in Latin America while also improving healthcare accessibility in private and institutional domains. With the aim of enabling a better quality of life for families and for the well-being of society in Latin America, Luminova Pharma Group presents itself not only as a frontrunner in the industry but also as an enabler of prosperity of the society.
